METABOLIK-CRISPR: INOVASI REKAYASA GENETIK TERTARGET DALAM MEMUTUS RANTAI RESISTENSI INSULIN KRONIS
Article Sidebar
Main Article Content
Abstract
Type 2 Diabetes Mellitus (T2DM) has emerged as a critical global health threat driven by chronic insulin resistance and pancreatic beta-cell dysfunction. Conventional therapies often fail to address the underlying molecular pathogenesis, focusing merely on glycemic control. This study aims to explore the potential of Metabolik-CRISPR, an innovative targeted genetic engineering approach, in breaking the chain of chronic insulin resistance. The method used is a comprehensive literature review analyzing recent advancements in CRISPR-Cas9 applications, ceRNA network regulations, and nanoparticle delivery systems. The results indicate that Metabolik-CRISPR effectively intervenes in critical signaling pathways (INSR, IRS1, AKT2) and corrects ceRNA network imbalances. Furthermore, the integration of Magnetic Peptide-Imprinted Nanoparticles (MPIPs) significantly enhances the targeted delivery and activation of endogenous insulin genes safely. In conclusion, Metabolik-CRISPR offers a fundamental, permanent, and comprehensive cellular rehabilitation strategy, shifting the paradigm of T2DM management from symptom amelioration to targeted genetic restoration.
Article Details
References
Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025;42:102037. doi: 10.1016/j.bbrep.2025.102037.
Mishu MA, Nath SK, Sohidullah M, Hossain MT. Advancement of animal and poultry nutrition: Harnessing the power of CRISPR-Cas genome editing technology. Int J Biol Macromol. 2023;224:124054. doi: 10.1016/j.ijbiomac.2023.124054.
Dayan CM, et al. Application of CRISPR-Cas9 technology in diabetes research. Diabet Med. 2024;41(1):e15240. doi: 10.1111/dme.15240.
El-Daly S, et al. Identification of Novel Insulin Resistance Related ceRNA Network in T2DM and Its Potential Editing by CRISPR/Cas9. Int J Mol Sci. 2021;22(15):8129. doi: 10.3390/ijms22158129.
Bora J, Dey A, Lyngdoh AR, et al. A critical review on therapeutic approaches of CRISPR-Cas9 in diabetes mellitus. Naunyn Schmiedebergs Arch Pharmacol. 2023. doi: 10.1007/s00210-023-02631-1.
Lee MH, Thomas JL, Lin CY, Li YCE, Lin HY. Activation of Insulin Gene Expression via Transfection of a CRISPR/Cas9a System Using Magnetic Peptide-Imprinted Nanoparticles. Pharmaceutics. 2023;15(4):1311. doi: 10.3390/pharmaceutics15041311.
Zhang J, et al. The CRISPR/Cas9 genome editing system in diabetes research. Diabetes. 2021;70(9):1962-1969. doi: 10.2337/dbi20-0047.
Dinic S, et al. Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front Endocrinol. 2022;13:1006376. doi: 10.3389/fendo.2022.1006376.
Macvanin MT, Gluvic Z, Bajic V, Isenovic ER. Novel insights regarding the role of noncoding RNAs in diabetes. World J Diabetes. 2023;14(7):958-976. doi: 10.4239/wjd.v14.17.958.
Beg MMA, et al. CRISPR as a Tool to Uncover Gene Function in Polycystic Ovary Syndrome: A Literature Review of Experimental Models Targeting Ovarian and Metabolic Genes. Cells. 2025;14(22):1769. doi: 10.3390/cells14221769.
Khan FA, et al. CRISPR/Cas9-Based Therapeutics as a Promising Strategy for Management of Alzheimer's Disease: Progress and Prospects. Front Cell Neurosci. 2025;19:1578138. doi: 10.3389/fncel.2025.1578138.
Uti DE, et al. Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment. Genes Dis. 2025. doi: 10.1177/11786388251408961.
ResearchGate. Overview of the CRISPR-Cas9 mechanism of action showing how in a bacterial cell the CRISPR RNA combined with tracrRNA to form a single guide RNA (sgRNA). [Online]. 2023. Available from: https://www.researchgate.net/figure/fig1_372783625.
Almohmadi NH, Zahran M, El-Nabtity SM, Shaheen HM. Prophylactic impacts of Lagenaria siceraria against cardiomyopathy induced by doxorubicin in a rat model. Braz J Biol. 2024;84:e276530. doi: 10.1590/1519-6984.276530.